Zobrazeno 1 - 10
of 14
pro vyhledávání: ''
Autor:
Rohit Mehra, Emmanuel S. Antonarakis, Javed Siddiqui, Felix Y. Feng, Costantine Albany, Przemyslaw Twardowski, Bruce Montgomery, Yi-Mi Wu, Karen E. Knudsen, Maha Hussain, Young E. Whang, Mark N. Stein, Dan R. Robinson, Daniel H. Shevrin, Arul M. Chinnaiyan, Megan E.V. Caram, Lakshmi P. Kunju, Walter M. Stadler, Kathleen A. Cooney, Xuhong Cao, Stephanie Daignault-Newton, Robert J. Lonigro, Paul G. Corn, David Smith, Scott A. Tomlins
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 10
Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients a
Autor:
Peter Kamper, Alexander Lindholm d'Amore, David W. Scott, Joseph M. Connors, Randy D. Gascoyne, Marcel Nijland, Sohrab P. Shah, Christian Steidl, Anja Mottok, Anke van den Berg, Stephen Hamilton-Dutoit, Fong Chun Chan, Alina S. Gerrie, Kerry J. Savage, Maryse M. Power, Arjan Diepstra, Francesco d'Amore
Publikováno v:
Chan, F C, Mottok, A, Gerrie, A S, Power, M, Nijland, M, Diepstra, A, van den Berg, A, Kamper, P, d'Amore, F, d'Amore, A L, Hamilton-Dutoit, S, Savage, K J, Shah, S P, Connors, J M, Gascoyne, R D, Scott, D W & Steidl, C 2017, ' Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma ', Journal of Clinical Oncology, vol. 35, no. 32, pp. 3722-3733 . https://doi.org/10.1200/JCO.2017.72.7925
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(32), 3722-3733. AMER SOC CLINICAL ONCOLOGY
Purpose Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods We performed
Autor:
James H. Doroshow, DW Visscher, Matthew P. Goetz, Stephanie L. Safgren, Vera J. Suman, Andrew T. Ralya, Michael A. Mahr, Tufia C. Haddad, James N. Ingle, Benjamin R. Kipp, Jerry M. Collins, Joel M. Reid, Charles Erlichman, Zachary R. Chalmers, Garrett M. Frampton, Alex A. Adjei, John R. Hawse, Don W. Northfelt, Travis J. Dockter, Minetta C. Liu, Mary J. Kuffel, Sarah A. Buhrow, Matthew M. Ames, John L. Black, Howard Streicher, Renee M. McGovern
Publikováno v:
Journal of Clinical Oncology. 35:3391-3400
Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity.
Autor:
J. Jack Lee, Lixia Diao, John V. Heymach, Ferdinandos Skoulidis, Sanjay Gupta, Ximing Tang, Waun Ki Hong, Kevin R. Coombes, David J. Mauro, Ignacio I. Wistuba, Vassiliki A. Papadimitrakopoulou, Vincent A. Miller, Ja Seok Koo, Caimiao Wei, Eric H. Rubin, Julie G. Izzo, Li Shen, Scott N. Gettinger, Anne S. Tsao, Neda Kalhor, Jing Wang, Lauren Averett Byers, S. Andrew Peng, Alda L. Tam, Don L. Gibbons, Frank V. Fossella, Sarah B. Goldberg, Roy S. Herbst
Publikováno v:
Journal of Clinical Oncology. 34:3638-3647
Purpose By applying the principles of real-time biopsy, biomarker-based, adaptively randomized studies in non–small-cell lung cancer (NSCLC) established by the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE)
Autor:
Malene Hildebrandt, Kirsten Falch, Sandra Duvnjak, Inguna Buskevica, Jeanette Ansholm Hansen, Marianne Ewertz, Lisbet Brønsro Larsen, Selma Bektas, Ziba Ahangarani Farahani, Oke Gerke, Katrine Lydolph Søe, Anne Marie Bak Jylling, Christina Baun, Abass Alavi, Henrik Gordon Petersen, Poul Flemming Høilund-Carlsen
Publikováno v:
Journal of Clinical Oncology. 34:1889-1897
Purpose To prospectively investigate the diagnostic accuracy of [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with dual-time-point imaging, contrast-enhanced CT (ceCT), and bone scintigraphy (BS) in patient
Autor:
Jeffrey E. Gershenwald, Charles R. Scoggins, Kelly M. McMasters, Peter D. Beitsch, B. Scott Davidson, Douglas S. Reintgen, Michael J. Edwards, Arnold J. Stromberg, James S. Goydos, Michael E. Egger, Marshall M. Urist, Stephan Ariyan, Jeffrey J. Sussman, Merrick I. Ross, Lee Hagendoorn, Robert C.G. Martin, R. Dirk Noyes
Publikováno v:
Journal of Clinical Oncology. 34:1079-1086
Purpose The Sunbelt Melanoma Trial is a prospective randomized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph node dissection (CLND) for patients with melanoma staged by sentinel lymph node (SLN) biopsy. P
Autor:
Herve Lang, Thierry Lebret, Christian Beisland, Luc Cormier, Claude Linassier, Antoine Thiery-Vuillemin, Simon Thezenas, Alain Ravaud, Sandra Colas, Laurent Guy, Karim Bensalah, Laurence Albiges, Michael Aitchison, Bernard Escudier, Marc Olivier Timsit, Lionnel Geoffroy, Gwenaelle Gravis, Frederic Rolland, Arnaud Mejean, Jean-Baptiste Beauval
Publikováno v:
Journal of Clinical Oncology. 36:LBA3-LBA3
LBA3 Background: Cytoreductive nephrectomy (CN) has been the standard of care in mRCC in the past twenty years, supported by randomized and large retrospective studies. However the efficacy of targeted therapies has challenged this standard. CARMENA
Autor:
Jose A. Karam, Eric Jonasch, Jianjun Gao, Jorge Blando, Matthew T. Campbell, Surena F. Matin, Yu Shen, Chaan S. Ng, Luis M Vence, Priya Rao, Hao Zhao, Sreyashi Basu, Amishi Yogesh Shah, Christopher G. Wood, Kamran Ahrar, Rebecca S. S. Tidwell, Amado J. Zurita, Nizar M. Tannir, Padmanee Sharma, James P. Allison
Publikováno v:
Journal of Clinical Oncology. 36:4520-4520
4501Background: Cytoreductive surgery (CS) including cytoreductive nephrectomy and metastasectomy provides clinical benefits to patients with MRCC. However, CS has not been evaluated in the setting...
Autor:
Rosina T. Lis, Kenneth J. Pienta, Peter Chang, Robert B. Montgomery, Glenn J. Bubley, Ashley E. Ross, Zhenwei Zhang, Rana R. McKay, Daniel W. Lin, William J. Ellis, Mary-Ellen Taplin, Huihui Ye, Adam S. Kibel, Wanling Xie, Andrew A. Wagner, Steven L. Chang, Quoc-Dien Trinh, Lauren C. Harshman
Publikováno v:
Journal of Clinical Oncology. 36:79-79
79 Background: Patients with high-risk PC have an increased risk of recurrence and mortality despite therapy. Abiraterone, a CYP17 inhibitor, and enzalutamide, a next generation anti-androgen, have demonstrated improved overall survival in metastatic
Autor:
Shakti H. Ramkissoon, David A. Reardon, Michael Lim, Paul Mulholland, Oliver M. Grauer, Lewis C. Strauss, Timothy F. Cloughesy, Ricardo Zwirtes, Solmaz Sahebjam, Joachim M. Baehring, Keith L. Ligon, Robert Latek
Publikováno v:
Journal of Clinical Oncology. 35:2001-2001
2001 Background: Patients treated with immunotherapies can have a transient increase in lesion size due to immune cell infiltration that is suggestive of disease progression, but undergo subsequent regression with continued treatment. For patients wi